Review ArticlePulmonary Hypertension Idiopathic Pulmonary Fibrosis: A Dastardly Duo
Section snippets
PREVALENCE
The prevalence of PH in the setting of IPF has not been well described in the literature, with a reported occurrence from 32% to 85%.5 This wide range is hypothesized to be because of RHC timing in the patients’ disease course. This disparity was addressed in a retrospective review of 39 IPF patients, where serial RHC was performed. Initial readings revealed a prevalence of 33%, whereas the second and third readings obtained closer to time of lung transplantation revealed an 85% prevalence.6 A
PATHOGENESIS
The pathogenesis of PH in the setting of IPF is complex and largely undefined. Several pathologic mechanisms have been implicated, including reduced endothelial cell prostacyclin production, elevated endothelin levels from enhanced production and reduced clearance, decreased nitric oxide synthase expression, decreased pulmonary vascular smooth muscle voltage-gated potassium channels, increase of proinflammatory cytokines and development of a prothrombotic state.9 Each of these processes favor
DIAGNOSIS
Diagnosis of PH in the setting of IPF can be challenging, relying on a high index of clinical suspicion as both signs and symptoms of each disease process share numerous clinical features, such as dyspnea, palpitations and chest discomfort. To date, there is no validated standardized clinical approach to evaluate an IPF patient who is suspected to have developed concurrent PH. The physical examination may provide the first clues. Patients may have an accentuated P2 component of the second heart
TREATMENT
The treatment of PH in patients with IPF is based on multiple factors, including disease severity, functional status and level of hypoxemia. Medications currently approved to treat PAH have been administered for PH in the setting of IPF, such as phosphodiesterase-5 inhibitors, nonselective endothelin receptor antagonists and prostacyclin analogues. PH experts and guidelines state that patients with more advanced PH including high-risk features should be considered for parenteral prostacyclin
CONCLUSIONS
IPF and PH convey a dismal prognosis in isolation and when combined, portend even worse outcomes. Diagnostically, recognizing underlying PH in the setting of IPF remains challenging because of nonspecific clinical symptoms and unrevealing ancillary testing. A high degree of clinical suspicion is paramount, as underlying PH will remain undetected. Currently, the only reliable diagnostic tool for PH is RHC, which is both invasive and costly. However, to make the correct diagnosis, RHC is
References (36)
- et al.
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis
Chest
(2006) - et al.
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Chest
(2005) - et al.
Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis
Respir Med
(2008) - et al.
Pulmonary hypertension: diagnosis and management
Mayo Clin Proc
(2009) - et al.
Pulmonary hypertension in idiopathic pulmonary fibrosis
Chest
(2007) - et al.
Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis
Chest
(2007) - et al.
Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Chest
(2008) - et al.
Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis
Respir Med
(2007) - et al.
Pulmonary hypertension in patients with interstitial lung diseases
Mayo Clin Proc
(2007) - et al.
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J Am Coll Cardiol
(2009)
Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension
Chest
A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease
Vascul Pharmacol
Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
Vascul Pharmacol
Sildenafil therapy in secondary pulmonary hypertension: is there benefit in prolonged use?
Vascul Pharmacol
Sildenafil improves walk distance in idiopathic pulmonary fibrosis
Chest
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Lancet
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension
Chest
Impact of secondary pulmonary hypertension on lung transplant outcome
J Heart Lung Transplant
Cited by (31)
Sirtuins as endogenous regulators of lung fibrosis: A current perspective
2020, Life SciencesCitation Excerpt :In fact, IPF most significantly accounts to the interstitial lung diseases. Pulmonary hypertension and right-sided heart failure (due to ventricular exhaustion by forceful pumping of blood through blocked pulmonary arteries) are some grave complications of IPF experienced at the advanced stages [45]. Post-translational modifications including acetylation, ADP ribosylation, acylation, sumoylation, succinylation, phosphorylation and methylation have always remained in the limelight as controllers of diverse pathogenesis.
Crocin attenuates lung inflammation and pulmonary vascular dysfunction in a rat model of bleomycin-induced pulmonary fibrosis
2019, Life SciencesCitation Excerpt :The potent antioxidant and anti-inflammatory effects of crocin could be amongst the mechanism by which they exert this observed protective effect. Pulmonary hypertension is a well-recognized complication of pulmonary fibrosis [53] and it is usually characterized by pulmonary arteriolar remodeling as well and this results in decreased responsiveness of pulmonary circulation to vasodilator therapies [54]. Indeed, BLM-induced lung fibrosis in the current study was associated with significant pulmonary vascular and tracheal functional impairments as seen within vitro assessment of vascular reactivity of isolated pulmonary artery rings to KCL, PE and carbachol.
Baccatin III ameliorates bleomycin-induced pulmonary fibrosis via suppression of TGF-β1 production and TGF-β1-induced fibroblast differentiation
2019, International ImmunopharmacologyCitation Excerpt :Idiopathic pulmonary fibrosis (IPF) is a severe public health problem worldwide that seriously threatens the health of humans [47]. Due to its rapid progress, poor prognosis, high morbidity and mortality, IPF has been termed a refractory lung disease [48]. The effectiveness of drugs used in the treatment of IPF is still obscure and is always accompanied by severe side-effects [49,50].
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software
2019, Respiratory MedicineCitation Excerpt :This section consists of four pages where users fill in yes/no questions regarding symptoms, radiological findings and histopathology. We also included precise domains for the evaluation of specific comorbidities to refine IPF diagnosis and exclude similar entities with potentially different outcomes [13–15]. In this section radiological and pathological interpretations must be provided reporting the presence/absence of specific features concordant or against the UIP pattern, in accordance with 2011 guidelines.
Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities
2018, Interstitial Lung DiseaseIdiopathic pulmonary fibrosis in west highland white terriers
2014, Veterinary Clinics of North America - Small Animal PracticeCitation Excerpt :They estimated that PHT was a frequent finding affecting more than 40% of the WHWTs in their study. Similarly, PHT is very common in humans with IPF and is related to increased mortality.39,40 HRCT provides superior evaluation of the lung parenchyma compared with conventional thoracic radiographs.
Curt J. Daniels is receiving grant funding outside of the submitted work. The remaining authors have no financial or other conflicts of interest to disclose.